Axsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 ...

Auvelity is approved for the treatment of adults with major depressive disorder (“MDD”). It is the first approved drug in Axsome’s portfolio. Auvelity was launched in the United States in 2022.

Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

The year-over-year increase in revenues can be attributed to strong sales of Auvelity (AXS-05). In the past year, shares of Axsome have rallied 41.3% against the industry’s decline of 8.8%.

Total net product revenue reached $386 million for 2024, with CEO Tabuteau stating, "Based on the recent performance, Auvelity is on track to reach blockbuster potential." Symbravo received FDA ...

The quarter was marked by strong sales from its commercial products, Auvelity and Sunosi, and heightened strategic investment in research and development (R&D) reflected in increased spending.

Axsome Therapeutics' Q4 revenue surged to $118.77 million, surpassing expectations with significant growth in Auvelity sales. Axsome reports progress on multiple drug applications, including ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity® 4Q and full year 2024 net product ...

Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA related to patents for the ...